Amgen (AMGN) is back in focus after a federal judge blocked Colorado’s proposed 70% price cap on Enbrel, which removed an immediate regulatory threat to one of the company’s key revenue drivers. See ...
Source LinkAmgen (AMGN) is back in focus after a federal judge blocked Colorado’s proposed 70% price cap on Enbrel, which removed an immediate regulatory threat to one of the company’s key revenue drivers. See ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.